Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells

Gene Therapy

Volumn 17, Issue 11, 2010, Pages 1333-1340

  Akbulut, H ^a   Tang, Y ^b   Akbulut, K G ^c   Maynard, J ^b   Deisseroth, A ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b SIDNEY KIMMEL CANCER CENTER   (United States)

^c GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

adenoviral vector; chemotherapy; cytosine deaminase; lung cancer cell; MUC 1

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CD40 LIGAND; FLUOROURACIL; MUCIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; GENE TARGETING; HUMAN; HUMAN CELL; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CD40 LIGAND; CELLS, CULTURED; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MUCIN-1; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED;

MUS;

EID: 78149466672     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.93     Document Type: Article

References (33)

1. Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired type 1T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 2004; 172: 3437-3446.
2. Weinberg AD, Thalhofer C, Morris N, Walker JM, Seiss D, Wong S et al. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother 2006; 29: 575-585.
3. Eaton SM, Burns EM, Kusser K, Randall TK, Haynes L. Age-related defects in CD4T cells cognate helper function lead to reductions in humoral responses. J Exp Med 2004; 200: 1613-1622.
4. Dong L, Mori I, Hossain J, Liu B, Kimura Y. An immunostimu-latory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response. J Gen Virol 2003; 84: 1623-1628.
5. Zhang L, Tang YC, Akbulut H, Zelterman D, Linton P-J, Deisseroth A. An adenoviral vector cancer vaccine. Proc Natl Acad Sci USA 2003; 100: 15202-15206.
6. Tang Y, Zhang L, Yuan J, Akbulut H, Maynard J, Linton PJ et al. Loading of APC by CD40 ligand/tumor antigen secretory protein generates protection from cancer cell lines. Blood 2004; 104: 2704-2713.
7. Tang YC, Maynard J, Akbulut H, Petersen L, Fang X, Zhang WW et al. Vector prime/protein boost vaccine which overcomes defects acquired during aging and cancer. J Immunol 2006; 177: 5697-5707.
8. Akbulut H, Tang Y, Maynard J, Zhang L, Pizzorno G, Deisseroth A. Vector-mediated delivery of 5FU. Clin Cancer Res 2004; 10: 7738-7746.
9. Akbulut H, Tang YC, Akbulut KG, Maynard J, Zhang L, Deisseroth A. Antitumor immune response induced by i.t. injection of vector activated dendritic cells and chemotherapy suppresses metastatic breast cancer. Mol Cancer Ther 2006; 5: 1975-1985.
10. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006; 66: 6063-6071.
11. LaPointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811-816.
12. Feng H, Ghazizadeh M, Konishi H, Araki T. Expression of MUC1 and MUC2 Mucin Gene Products in Human Ovarian Carcinomas. Japanese J Clin Oncol 2002; 32: 525-529.
13. Tamada Y, Takeuchi H, Suzuki N, Susumu N, Aoki D, Irimura T. Biological and therapeutic significance of MUC1 with sialogly-cans in clear cell adenocarcinoma of the ovary. Cancer Sci 2007; 98: 1586-1591.
14. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death from cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115: 1503-1521.
15. Liu R, Wang XH, Chen GY, Dalerba P, Gurney A, Hoey T et al. The prognostic role of a gene signature from tumorigenic breast cancer cells. New England J Med 2007; 356: 217-226.
16. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L et al. Isolation of rara circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-1241.
17. Terstappen LWMM. Monitoring and characterization of circulat¬ing tumor cells in cancer patients. In: American Association for Cancer Research 99th Annual Meetiung Education Book; 2008 Aor 12-16. AACR: San Diego, CA, USA, 2008, pp 617-624.
18. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006; 5: 1886-1901.
19. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006; 12: 5615-5621.
20. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierachy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
21. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodefi-cient mice. Nature 2007; 445: 106-110.
22. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
23. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M et al. Identification of cells initiating human melanomas. Nature 2008; 451: 345-349.
24. Engelmann K, Shen HM, Finn OJ. CDF7 side population cells with characteristics of stem/progenitor cells express the tumor antigen MUC-1. Cancer Res 2008; 68: 2419-2426.
25. Mahanta SJ, Fessler SP, Park JH, Bamdad C. A minimal fragment of MUC1 mediates growth of cancer cells. PLoS ONE 2008; 3: e2054.
26. Hikita ST, Kosik KS, Clegg DO, Bamdad C. MUC1 mediates the growth of human pluripotent stem cells. PLoS ONE 2008; 3: e3312.
27. Tang YC, Akbulut H, Maynard J, Zhang L, Petersen L, Deisseroth A. Vaccine strategies for cancer and infectious diseases in the elderly. In: Chiai T, Shimada H, Tagawa M (eds). Gene Therapy 2007: Japanese Ministry of Science and Education: Chiba, Japan, 2007, pp 78-85.
28. Akbulut H, Zhang L, Tang Y, Deisseroth AB. The efficiency of replication-competent adenoviral vectors carrying L-plastin promoted cytosine deaminase gene in colon cancer. Cancer Gene Ther 2003; 10: 388-395.
29. Zhang L, Akbulut H, Peng XY, Pizzorno G, Deisseroth AB. Adenoviral vectors with E1A Tumor specific promoters are selectively cytolytic for breast cancer and on melanoma. Mol Ther 2002; 6: 386-393.
30. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
31. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cdell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 4727-4733.
32. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U et al. A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-14233.
33. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D et al. Purification and unique properties of mammary epithelial stem cells. Nature 2006; 439: 993-997.